BR0008779A - Composições e métodos para tratamento de infecções estafilocócicas - Google Patents
Composições e métodos para tratamento de infecções estafilocócicasInfo
- Publication number
- BR0008779A BR0008779A BR0008779-3A BR0008779A BR0008779A BR 0008779 A BR0008779 A BR 0008779A BR 0008779 A BR0008779 A BR 0008779A BR 0008779 A BR0008779 A BR 0008779A
- Authority
- BR
- Brazil
- Prior art keywords
- antibiotic
- compositions
- cell wall
- methods
- staphylococcal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24075—Lysostaphin (3.4.24.75)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"COMPOSIçõES E MéTODOS PARA TRATAMENTO DE INFECçõES ESTAFILOCóCICAS". Co-administração de uma lisostafina ou outro agente antiestafilocócico que cliva as ligações cruzadas de peptidoglicanos de paredes de células estafilocócicas tal como a lisostafina e um antibiótico eficaz contra o estafilococos devido à atividade antibiótica mediada por atividade de parede celular é eficaz contra a infecção estafilocócica, mesmo estafilococos que podem ser resistentes a um ou outro de lisostafina ou o antibiótico ativo de parede celular. A co-administração simultaneamente suprime a geração de cepas mutantes resistentes a antibiótico. Antibióticos ativos de parede celular eficazes incluem os <225>-lactamas e glicopeptídeos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/263,776 US6569830B1 (en) | 1999-03-05 | 1999-03-05 | Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains |
PCT/US2000/005464 WO2000051588A1 (en) | 1999-03-05 | 2000-03-03 | Compositions and methods for treatment of staphylococcal infection |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0008779A true BR0008779A (pt) | 2002-10-15 |
Family
ID=23003182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0008779-3A BR0008779A (pt) | 1999-03-05 | 2000-03-03 | Composições e métodos para tratamento de infecções estafilocócicas |
Country Status (14)
Country | Link |
---|---|
US (4) | US6569830B1 (pt) |
EP (1) | EP1181011A4 (pt) |
JP (1) | JP2002538108A (pt) |
KR (1) | KR20020010893A (pt) |
CN (1) | CN1353602A (pt) |
AR (1) | AR022791A1 (pt) |
AU (1) | AU780864B2 (pt) |
BR (1) | BR0008779A (pt) |
CA (1) | CA2362487A1 (pt) |
IL (1) | IL145282A0 (pt) |
NO (1) | NO20014314L (pt) |
PL (1) | PL364875A1 (pt) |
WO (1) | WO2000051588A1 (pt) |
ZA (1) | ZA200108215B (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569830B1 (en) | 1999-03-05 | 2003-05-27 | Ambi, Inc. | Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains |
GB0212622D0 (en) * | 2002-05-31 | 2002-07-10 | Natural Technologies Group Ltd | Bacterial transforming agent |
AU2003298770A1 (en) * | 2002-12-02 | 2004-06-23 | Biosynexus Inc | Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines |
KR20060132698A (ko) * | 2004-01-23 | 2006-12-21 | 니리어스 파마슈티컬즈, 인코퍼레이션 | 항균제로 유용한 비스-인돌 피롤 |
US7522663B2 (en) * | 2005-03-10 | 2009-04-21 | Stmicroelectronics, Inc. | Burst error limiting feedback equalizer system and method for multidimensional modulation systems |
US20100080790A1 (en) * | 2005-07-13 | 2010-04-01 | University Of South Carolina | Sterilization using high-pressure carbon dioxide |
GB0600928D0 (en) | 2006-01-17 | 2006-02-22 | Novacta Biosystems Ltd | Improvements relating to lantibiotics |
US20080014572A1 (en) * | 2006-07-13 | 2008-01-17 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for molecular inhibition |
US20090082344A1 (en) * | 2006-07-13 | 2009-03-26 | Searete Llc | Methods and systems for treating disease |
US20080015833A1 (en) * | 2006-07-13 | 2008-01-17 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for molecular inhibition of protein misfolding |
US20080015835A1 (en) * | 2006-07-13 | 2008-01-17 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for treating disease |
GB0714030D0 (en) * | 2007-07-18 | 2007-08-29 | Novacta Biosystems Ltd | The use of type-B lantibiotic-based compounds having antimicrobial activity |
GB0714029D0 (en) * | 2007-07-18 | 2007-08-29 | Novacta Biosystems Ltd | Lantibiotic-based compounds having antimicrobial activity |
US20110044968A1 (en) * | 2008-03-10 | 2011-02-24 | Pharmal N Corporation | Compositions for treatment with metallopeptidases, methods of making and using the same |
WO2009152298A1 (en) * | 2008-06-13 | 2009-12-17 | Zeus Scientific, Inc. | Methods, compositions and and diagnostic kits for the detection and treatment for staphylococcal nasal decolonization using achromopeptidase |
NZ594011A (en) | 2009-01-14 | 2013-12-20 | Novacta Biosystems Ltd | Deoxyactagardine derivatives |
WO2010089544A1 (en) | 2009-02-04 | 2010-08-12 | Novacta Biosystems Limited | Actagardine derivatives |
GB201001688D0 (en) | 2010-02-02 | 2010-03-17 | Novacta Biosystems Ltd | Compounds |
GB201013513D0 (en) | 2010-08-11 | 2010-09-22 | Novacta Biosystems Ltd | Formulations |
WO2014071198A1 (en) * | 2012-11-01 | 2014-05-08 | The University Of Chicago | Antibiotic methods and compositions for bacteria infections |
CA2934670A1 (en) * | 2013-12-28 | 2015-07-02 | StaphRx, LLC | Ultra-low dose lysostaphin for treating mrsa |
CN106795506B (zh) | 2014-05-14 | 2020-11-27 | 达特茅斯学院理事会 | 去免疫化溶葡萄球菌酶和使用方法 |
US11744859B2 (en) | 2017-07-07 | 2023-09-05 | Epicentrx, Inc. | Compositions and methods for parenteral administration of therapeutic agents |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3278378A (en) | 1962-04-19 | 1966-10-11 | Schindler Charles Alvin | Staphylococcus-derived antibiotic |
US3398056A (en) | 1964-07-10 | 1968-08-20 | Mead Johnson & Co | Process for producing lysostaphin by fermentation |
US3594284A (en) | 1968-06-04 | 1971-07-20 | Mead Johnson & Co | Lysostaphin fermentation with accelerated time cycle |
US4931390A (en) | 1986-04-16 | 1990-06-05 | Public Health Research Institute Of The City Of New York, Inc. | Expression of the cloned lysostaphin gene |
US5858962A (en) | 1987-05-11 | 1999-01-12 | Ambi Inc. | Composition for treating mastitis and other staphylococcal infections |
US5304540A (en) | 1988-06-22 | 1994-04-19 | Applied Microbiology, Inc. | Pharmaceutical bacteriocin compositions and methods for using the same |
AU623864B2 (en) | 1988-08-29 | 1992-05-28 | Applied Microbiology, Inc | Method of treating mastitis and other staphylococcal infections |
JPH0645553B2 (ja) * | 1988-09-19 | 1994-06-15 | アプライド マイクロバイオロジィ,インコーポレイテッド | 乳房炎およびその他のブドウ球菌感染症の治療法並びに同治療用組成物 |
US5466685A (en) | 1993-05-13 | 1995-11-14 | Johnson & Johnson | Inhibition of expression of beta-lactamase using esters of fatty acid alcohols |
US6028051A (en) | 1997-07-23 | 2000-02-22 | Ambi Inc. | Method for the treatment of staphylococcal disease |
PL338178A1 (en) * | 1997-07-23 | 2000-10-09 | Ambi Inc | Pharmaceutic composition containing sole lysotaphin or in combination with an antibiotic for treating staphylococcal infections |
US6569830B1 (en) | 1999-03-05 | 2003-05-27 | Ambi, Inc. | Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains |
-
1999
- 1999-03-05 US US09/263,776 patent/US6569830B1/en not_active Expired - Fee Related
-
2000
- 2000-02-29 AR ARP000100885A patent/AR022791A1/es unknown
- 2000-03-03 CA CA002362487A patent/CA2362487A1/en not_active Abandoned
- 2000-03-03 BR BR0008779-3A patent/BR0008779A/pt not_active Application Discontinuation
- 2000-03-03 PL PL00364875A patent/PL364875A1/xx unknown
- 2000-03-03 AU AU32490/00A patent/AU780864B2/en not_active Ceased
- 2000-03-03 EP EP00910390A patent/EP1181011A4/en not_active Withdrawn
- 2000-03-03 CN CN00804527A patent/CN1353602A/zh active Pending
- 2000-03-03 WO PCT/US2000/005464 patent/WO2000051588A1/en not_active Application Discontinuation
- 2000-03-03 IL IL14528200A patent/IL145282A0/xx unknown
- 2000-03-03 JP JP2000602056A patent/JP2002538108A/ja active Pending
- 2000-03-03 KR KR1020017011309A patent/KR20020010893A/ko not_active Application Discontinuation
- 2000-09-19 US US09/665,077 patent/US7078377B1/en not_active Expired - Fee Related
-
2001
- 2001-09-05 NO NO20014314A patent/NO20014314L/no unknown
- 2001-10-05 ZA ZA200108215A patent/ZA200108215B/xx unknown
-
2003
- 2003-04-16 US US10/414,566 patent/US7122514B2/en not_active Expired - Fee Related
-
2006
- 2006-06-02 US US11/445,289 patent/US8198231B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1353602A (zh) | 2002-06-12 |
AU3249000A (en) | 2000-09-21 |
US20030199432A1 (en) | 2003-10-23 |
US7078377B1 (en) | 2006-07-18 |
EP1181011A1 (en) | 2002-02-27 |
AR022791A1 (es) | 2002-09-04 |
IL145282A0 (en) | 2002-06-30 |
AU780864B2 (en) | 2005-04-21 |
US20060246055A1 (en) | 2006-11-02 |
CA2362487A1 (en) | 2000-09-08 |
KR20020010893A (ko) | 2002-02-06 |
WO2000051588A1 (en) | 2000-09-08 |
PL364875A1 (en) | 2004-12-27 |
ZA200108215B (en) | 2006-03-29 |
US7122514B2 (en) | 2006-10-17 |
EP1181011A4 (en) | 2003-05-21 |
US8198231B2 (en) | 2012-06-12 |
NO20014314L (no) | 2001-10-11 |
US6569830B1 (en) | 2003-05-27 |
NO20014314D0 (no) | 2001-09-05 |
JP2002538108A (ja) | 2002-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0008779A (pt) | Composições e métodos para tratamento de infecções estafilocócicas | |
BR0110420A (pt) | Agonistas muscarìnicos | |
PT750618E (pt) | Derivados de oxazolidinona e composicoes farmaceuticas que os contem | |
ID21526A (id) | 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus | |
ES2176600T3 (es) | Derivado de la propiofenona y procedimientos para su preparacion. | |
GB2388786A (en) | Dental floss with usage identification capability | |
FI932390A (fi) | Nya hydroxiaminsyra- och N-hydroxiureaderivat samt deras anvaendning | |
NO971471L (no) | Nye karboksamider med fungicid aktivitet | |
BR9710768A (pt) | Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i | |
UA37181C2 (uk) | ГІДРОХЛОРИД 7-<font face="Symbol">b</font>-[(Z)-2-(2-АМІНО-4-ТІАЗОЛІЛ)-3-ГІДРОКСИІМІНОАЦЕТА- МІДО]-3-(1,2,3-ТРИАЗОЛ-4-ІЛ)ТІОМЕТИЛТІО-3-ЦЕФЕМ-4-КАРБОНОВОЇ КИСЛОТИ АБО ЙОГО ГІДРАТИ, ЩО МАЮТЬ АНТИБАКТЕРІАЛЬНУ ДІЮ, ФАРМАЦЕВТИЧНА АНТИБАКТЕРІАЛЬНА КОМПОЗИЦІЯ, СПОСІБ ПРИГНІЧЕННЯ РОЗВИТКУ БАКТЕРІЙ, СПОСІБ ЛІКУВАННЯ БАКТЕРІАЛЬНИХ ІНФЕКЦІЙ | |
ES2161785T3 (es) | Emplasto para el tratamiento de micosis ungulares. | |
BR9714287A (pt) | Antibiótico cristalino designado solvato 6-o-metileritromicina forma 0, solvato de 6-o-metileritromicina forma 0, composição, processos para tratamento de infecções bacterianas em um mamìfero hospedeiro com necessidade de tal tratamento e para preparação de solvato de 6-o-metileritomicina a forma 0, 6-o-metileritromicina forma 0--etanolato, suspensão para administração oral, e, complexo de solvato de 6-o-metileritromicina a forma 0-carbÈmero. | |
ATE218581T1 (de) | Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung | |
BR9811535A (pt) | Composições farmacêuticas contendo lisostafina sozinha ou em combinação com um antibiótico para o tratamento de infecções por estafilocócico | |
ATE344269T1 (de) | Carbamat und carbazat ketolid antibiotika | |
BR9813985A (pt) | Derivados de oxazolidinona e composições farmacêuticas | |
TR200400363T4 (tr) | Antibiyotikten / Antibiyotiklerden oluşan bir preparatın imalatı ve kullanımı | |
BR9913738A (pt) | Composições e métodos de sanitização | |
BR0011225A (pt) | Agente para tratar de olhos secos, seu método e uso | |
BR0113389A (pt) | Compostos que inibem a atividade do fator xa | |
AU3902299A (en) | Methods of treating microbial infection and therapeutic formulations therefor | |
DE69430385D1 (de) | Hiv-proteaseinhibitoren | |
DE60034879D1 (en) | Lantibiotikum | |
AR029544A1 (es) | Composiciones y metodos para tratar infecciones bacterianas | |
DE3875349D1 (de) | Glykosaminoglykan zur behandlung von diabetischer mikroangiopathie. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |